RxDoctor Payments DataLook up a doctor →

Cheryl Mejia, DO

Physical Medicine & Rehabilitation · Hagerstown, MDNPI 1003189515

Payments from drug & device makers

$19,684in general payments, 2019–2025

Across 456 payments — averaging $43.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$7K
  • Nevro Corp.$2K
  • Boston Scientific$2K
  • Biodelivery Sciences International, Inc.$2K
  • Collegium Pharmaceutical, Inc.$1K
  • Vertos Medical, Inc.$681
  • plus $4K from 35 others

What the payments were for

  • Speaking & faculty fees$7,53038%
  • Travel & lodging$3,87620%
  • Food & beverage$8,17542%
  • Education$1031%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,684 in reported general payments places this provider in the 95th percentile of 202 physical medicine & rehabilitation providers in Maryland.

See all physical medicine & rehabilitation providers in Maryland

Medicare billing

Part B allowed, 2024
$326,086
Medicare patients
742
Services billed
4,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl57$38,016
Buprenorphine171$32,576
Xtampza ErOxycodone Myristate56$24,440
MovantikNaloxegol Oxalate27$12,119
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen314$10,893
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen341$10,568
LinzessLinaclotide14$10,182
OxycontinOxycodone Hcl19$7,515
Oxycodone Hcl351$6,165
Gabapentin517$6,102
Morphine Sulfate ErMorphine Sulfate247$6,014
Naloxone Hcl73$4,100
Pregabalin167$4,032
Tramadol Hcl273$2,983
Lidocaine31$2,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$1,260$62,455113 claims
Redhill Biopharma Inc.Movantik$38$12,11927 claims
AbbVieLinzess$203$10,18214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 202 physical medicine & rehabilitation providers in Maryland.

Other physical medicine & rehabilitation in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →